Aliases & Classifications for Arthritis

MalaCards integrated aliases for Arthritis:

Name: Arthritis 39 12 77 30 56 6 44 45 15 17 74 3
Inflammatory Joint Disease 56 74
Inflammatory Disorder of Joint 12

Classifications:



External Ids:

Disease Ontology 12 DOID:848
MeSH 45 D001168
NCIt 51 C2883
SNOMED-CT 69 3723001

Summaries for Arthritis

MedlinePlus : 44 If you feel pain and stiffness in your body or have trouble moving around, you might have arthritis. Most kinds of arthritis cause pain and swelling in your joints. Joints are places where two bones meet, such as your elbow or knee. Over time, a swollen joint can become severely damaged. Some kinds of arthritis can also cause problems in your organs, such as your eyes or skin. Types of arthritis include Osteoarthritis is the most common type of arthritis. It's often related to aging or to an injury. Autoimmune arthritis happens when your body's immune system attacks healthy cells in your body by mistake. Rheumatoid arthritis is the most common form of this kind of arthritis. Juvenile arthritis is a type of arthritis that happens in children. Infectious arthritis is an infection that has spread from another part of the body to the joint. Psoriatic arthritis affects people with psoriasis. Gout is a painful type of arthritis that happens when too much uric acid builds up in the body. It often starts in the big toe. NIH: National Institute of Arthritis and Musculoskeletal and Skin Diseases

MalaCards based summary : Arthritis, also known as inflammatory joint disease, is related to juvenile rheumatoid arthritis and systemic onset juvenile idiopathic arthritis, and has symptoms including joint stiffness, arthralgia and back pain. An important gene associated with Arthritis is CPT2 (Carnitine Palmitoyltransferase 2), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Rayos and leucovorin have been mentioned in the context of this disorder. Affiliated tissues include bone, t cells and testes, and related phenotypes are Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression and homeostasis/metabolism

Disease Ontology : 12 A bone inflammation disease that involves a response to irritation or injury, characterized by joint pain, swelling, stiffness located in joint and/or redness located in skin over the joint.

CDC : 3 Arthritis affects 54.4 million US adults, about 1 in 4. It is a major cause of work disability in the United States and one of the most common chronic conditions in the nation. Arthritis is a common cause of chronic pain.

Wikipedia : 77 Arthritis is a term often used to mean any disorder that affects joints.Symptoms generally include joint... more...

Related Diseases for Arthritis

Diseases in the Arthritis family:

Transient Arthritis

Diseases related to Arthritis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1647)
# Related Disease Score Top Affiliating Genes
1 juvenile rheumatoid arthritis 35.0 IL1B IL6 LTA TNF
2 systemic onset juvenile idiopathic arthritis 34.7 MIF TNF
3 rheumatoid arthritis, systemic juvenile 34.6 IL6 LACC1 MIF
4 psoriatic arthritis 34.4 IL17A IL1A IL1B IL6 LTA MMP1
5 spondyloarthropathy 1 34.1 IL17A MMP3 TNF
6 polyarticular onset juvenile idiopathic arthritis 34.1 TNFRSF11A TNFSF11
7 oligoarticular juvenile idiopathic arthritis 34.0 MIF PTPN22 TNF
8 osteoarthritis 33.7 IL1B IL6 MMP1 MMP13 MMP3 TNF
9 rheumatoid arthritis 33.5 CCL2 CXCL8 IL17A IL1A IL1B IL6
10 adult-onset still's disease 33.3 IL1B IL6 MIF TNF
11 palindromic rheumatism 33.2 IL1B PTPN22 TNF
12 joint disorders 32.7 IL17A IL1B IL6 MMP3 TNF TNFSF11
13 lyme disease 32.7 IL17A IL1B IL6 MMP9 TNF
14 sarcoidosis 1 32.7 IL1B LTA TNF
15 rheumatoid nodulosis 32.7 MMP3 MMP9
16 behcet syndrome 32.6 CXCL8 IL17A IL1B IL6 LTA PSTPIP1
17 temporal arteritis 32.6 CCL2 IL6 PTPN22 TNF
18 rosacea 32.6 IL6 MMP9 TNF
19 familial mediterranean fever 32.5 IL1B PSTPIP1 SAA1 TNF
20 brucellosis 32.4 CXCL8 IL6 SAA1 TNF
21 bronchiolitis obliterans 32.4 CXCL8 IL17A IL6 MMP9 TNF
22 interstitial lung disease 32.3 CCL2 CXCL8 IL1A IL1B IL6 MMP9
23 osteoporosis 32.2 IL1A IL1B IL6 TNF TNFRSF11A TNFSF11
24 bone disease 32.1 IL1B IL6 MMP13 TNF TNFRSF11A TNFSF11
25 systemic lupus erythematosus 32.1 CCL2 IL17A IL1B IL6 LTA PTPN22
26 tropical spastic paraparesis 32.1 IL17A IL6 MMP9
27 spondylitis 31.8 IL17A IL6 LTA TNF
28 uveitis 31.6 CCL2 IL17A IL1A TNF
29 pericarditis 31.4 IL1B IL6 TNF
30 osteomyelitis 31.3 CXCL8 IL1A IL1B IL6 TNF TNFSF11
31 synovitis 31.3 CXCL8 IL1B IL6 MMP1 MMP13 MMP3
32 pyoderma gangrenosum 31.2 CXCL8 PSTPIP1 TNF
33 autoimmune disease 31.2 IL17A IL1B IL6 PTPN22 TNF
34 lung disease 31.2 CCL2 CXCL8 IL17A IL1B IL6 MMP9
35 spondyloarthropathy 31.2 IL17A IL6 MMP3 TNF TNFSF11
36 pneumonia 31.2 CCL2 CXCL8 IL1B IL6 TNF
37 chlamydia 31.2 CXCL8 IL1A IL1B IL6 TNF
38 chikungunya 31.2 CCL2 IL1B IL6 TNF
39 atherosclerosis susceptibility 31.1 CCL2 IL6 TNF
40 bone resorption disease 31.1 IL6 TNFRSF11A TNFSF11
41 pyoderma 31.1 CXCL8 MMP9 PSTPIP1 TNF
42 endocarditis 31.1 CXCL8 IL6 TNF
43 diabetes mellitus 31.0 IL1A IL1B IL6 LTA PTPN22 TNF
44 heart disease 31.0 CXCL8 IL1B IL6 MMP3 TNF
45 leishmaniasis 31.0 IL1A IL1B TNF
46 inflammatory bowel disease 30.9 CXCL8 IL17A IL1B IL6 TNF
47 acquired immunodeficiency syndrome 30.9 IL1B IL6 TNF
48 colitis 30.9 CXCL8 IL17A IL1B IL6 LACC1 TNF
49 bronchiolitis 30.8 CXCL8 IL17A IL6 TNF
50 haemophilus influenzae 30.8 CXCL8 IL1B TNF

Graphical network of the top 20 diseases related to Arthritis:



Diseases related to Arthritis

Symptoms & Phenotypes for Arthritis

UMLS symptoms related to Arthritis:


joint stiffness, arthralgia, back pain, sciatica, muscle cramp, metatarsalgia

GenomeRNAi Phenotypes related to Arthritis according to GeneCards Suite gene sharing:

27
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased Tat-dependent HIV-LTR-beta-galactosidase protein expression GR00224-A-2 8.8 IL1A MMP13 MMP9

MGI Mouse Phenotypes related to Arthritis:

47
# Description MGI Source Accession Score Top Affiliating Genes
1 homeostasis/metabolism MP:0005376 10.3 CPT2 IL17A IL1A IL1B IL6 LACC1
2 hematopoietic system MP:0005397 10.25 IL17A IL1A IL1B IL6 LACC1 LTA
3 immune system MP:0005387 10.25 CCL2 CPT2 IL17A IL1A IL1B IL6
4 integument MP:0010771 9.86 IL1A IL1B IL6 MMP13 MMP9 TNF
5 neoplasm MP:0002006 9.81 IL1A IL1B IL6 MIF MMP1 MMP9
6 respiratory system MP:0005388 9.61 CPT2 IL17A IL6 LTA MMP9 PTPN22
7 skeleton MP:0005390 9.36 CPT2 IL17A IL1B IL6 LTA MMP13

Drugs & Therapeutics for Arthritis

FDA approved drugs:

# Drug Name Active Ingredient(s) 19 Company Approval Date
1
Rayos 19 PREDNISONE Horizon Pharma July of 2012

Drugs for Arthritis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1119)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
leucovorin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
2
Methotrexate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 1959-05-2, 59-05-2 126941
3
Leflunomide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75706-12-6 3899
4
Etanercept Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 185243-69-0
5
Infliximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 170277-31-3
6
Adalimumab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 331731-18-1 16219006
7
Abatacept Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 332348-12-6 10237
8
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 174722-31-7 10201696
9
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 302-25-0
10
Methylprednisolone hemisuccinate Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 2921-57-5
11
Prednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 50-24-8 5755
12
Naltrexone Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2 16590-41-3 5360515
13
Methylprednisolone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 83-43-2 6741
14
Hydroxychloroquine Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 118-42-3 3652
15
Sulfasalazine Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 599-79-1 5353980 5359476
16
Ethanol Approved Phase 4,Phase 3,Phase 2,Not Applicable 64-17-5 702
17
Etoricoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 202409-33-4 123619
18
Diclofenac Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 15307-86-5 3033
19
Certolizumab pegol Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 428863-50-7
20
Cimetidine Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 51481-61-9 2756
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 1177-87-3
22
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 50-02-2 5743
23
Glucosamine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 3416-24-8 439213
24
Spironolactone Approved Phase 4,Phase 2 52-01-7, 1952-01-7 5833
25
Naproxen Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22204-53-1 156391 1302
26
Celecoxib Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 169590-42-5 2662
27
Esomeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 161796-78-7, 119141-88-7, 161973-10-0 9568614 4594
28
Hyaluronic acid Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 9004-61-9 53477741
29
Dimethyl fumarate Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 624-49-7 637568 5271565
30
Zinc Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 7440-66-6 32051
31
Acetaminophen Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 103-90-2 1983
32
Polidocanol Approved Phase 4 9002-92-0
33
Azithromycin Approved Phase 4,Phase 3 83905-01-5 55185 447043
34
Prednisone Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 53-03-2 5865
35
Thrombin Approved, Investigational Phase 4,Phase 1
36
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
37
Tranexamic Acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 1197-18-8 5526
38
Rivaroxaban Approved Phase 4,Phase 3,Phase 2,Not Applicable 366789-02-8
39
Triamcinolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 124-94-7 31307
40
Enoxaparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6 772
41
Dalteparin Approved Phase 4,Phase 3,Not Applicable 9005-49-6
42
Heparin Approved, Investigational Phase 4,Phase 3,Not Applicable 9005-49-6 772 46507594
43
Acetylcholine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 51-84-3 187
44
Lidocaine Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 137-58-6 3676
45
Betamethasone Approved, Vet_approved Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable 378-44-9 9782
46
Ketorolac Approved Phase 4,Phase 3,Phase 2,Not Applicable 66635-83-4, 74103-06-3 3826
47
Iron Approved, Experimental Phase 4,Phase 1,Phase 2,Not Applicable 7439-89-6, 15438-31-0 23925 27284
48
Chitosan Approved Phase 4,Not Applicable 9012-76-4 71853
49
Ropivacaine Approved Phase 4,Phase 3,Phase 2,Not Applicable 84057-95-4 71273 175805
50
Hyoscyamine Approved Phase 4,Not Applicable 101-31-5 64692

Interventional clinical trials:

(show top 50) (show all 7740)
# Name Status NCT ID Phase Drugs
1 Uncontrolled Study to Evaluate Efficacy of Tocilizumab in Patients With Moderate or Severe Rheumatoid Arthritis Unknown status NCT02087696 Phase 4 Tocilizumab
2 Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis Unknown status NCT01939132 Phase 4 Open label H.P. Acthar Gel
3 Effect of Monoclonal Anti-IL6 Antibody (Tocilizumab) on the Cardiovascular Risk in Patients With Rheumatoid Arthritis Unknown status NCT01752335 Phase 4
4 Efficacy Study of Leflunomide to Treat Juvenile Idiopathic Arthritis Unknown status NCT02024334 Phase 4 Leflunomide
5 Etanercept and Methotrexate in Patients to Induce Remission in Early Arthritis (EMPIRE) Unknown status NCT01303874 Phase 4 Etanercept (ETN);Placebo
6 Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for Rheumatoid Arthritis Unknown status NCT01000441 Phase 4 infliximab, etanercept, adalimumab;abatacept, rituximab or tocilizumab
7 Multicenter Randomized Prospective Trial Comparing Methotrexate Alone or in Combination With Adalimumab in Early Arthritis Unknown status NCT00291915 Phase 4 Adalimumab;Methotrexate
8 Effectiveness of Iguratimod Versus Placebo to Treat Early Rheumatoid Arthritis on MRI Unknown status NCT01893151 Phase 4 Iguratimod;Iguratimod placebo
9 Kunxian for the Treatment of Rheumatoid Arthritis Unknown status NCT02764515 Phase 4 Kunxian Capsule;Methotrexate
10 Long-term Efficacy of Iguratimod Alone or Iguratimod in Combination With Methotrexate in Patients With Rheumatoid Arthritis Unknown status NCT01548001 Phase 4 Iguratimod;Methotrexate
11 Vaccination Against Pertussis, Tetanus and Diphtheria in Patients Suffering From Rheumatoid Arthritis Unknown status NCT01301703 Phase 4
12 The Effect of Biannual Monitoring With Magnetic Resonance Imaging (MRI), X-ray, or Usual Care on Treatment for Inflammatory Arthritis Unknown status NCT00808496 Phase 4
13 Inhibition of Co-Stimulation in Rheumatoid Arthritis Unknown status NCT02652273 Phase 4 Abatacept
14 Withdrawal of Etanercept After Successful Treatment of Juvenile Idiopathic Arthritis Unknown status NCT01287715 Phase 4 etanercept;etanercept
15 TNF-blocking Therapy in Combination With Disease-modifying Antirheumatic Drugs in Early Rheumatoid Arthritis Unknown status NCT00908089 Phase 4 Trexan+Salazopyrin+Oxiklorin+prednisolone + infliximab;Trexan+Salazopyrin+Oxiklorin+prednisolone + placebo
16 Efficacy, Radiographic and Laboratory Changes in Refractory Rheumatoid Arthritis Patients Treated With H.P. Acthar Gel Unknown status NCT03082573 Phase 4 H.P. Acthar gel
17 Study of Iguratimod Plus Methotrexate Compared to Leflunomid Plus Methotrexate in Patients With Rheumatoid Arthritis Unknown status NCT02275299 Phase 4 Iguratimod;Leflunomide;Methotrexate
18 Remission Induction in Very Early Rheumatoid Arthritis Unknown status NCT00523692 Phase 4 Etanercept, methotrexate and depomedrone;depemedrone
19 Targeting Synovitis in Early Rheumatoid Arthritis Unknown status NCT00920478 Phase 4
20 Cell Immunity Response to Vaccination Against Influenza in Patients With Rheumatoid Arthritis Unknown status NCT01002716 Phase 4
21 REstore Working Ability in RheumatoiD Arthritis Unknown status NCT01405326 Phase 4
22 Comparison of the Effect of Etoricoxib and Diclofenac on Early Morning Activity in Rheumatoid Arthritis (RA) Unknown status NCT01067430 Phase 4 Etoricoxib;Diclofenac
23 Heart Function in Rheumatoid Arthritis and Ankylosing Spondylitis Pre and Post-TNF Blocker Unknown status NCT01072058 Phase 4 TNF blockers (infliximab, adalimumab, etanercept)
24 Rheumatoid Arthritis Patients in Training Unknown status NCT00434200 Phase 4
25 Evaluation Effects of Treatment With IL-6R Inhibitor on Clinical Response and Biomarkers in Patients With Rheumatoid Arthritis (RA) Not Responding to DMARDs and/or a First Biological Agent. Unknown status NCT01835613 Phase 4
26 Effects of Biological Treatment on Blood Pressure and Endothelial Function in Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis Unknown status NCT02132234 Phase 4 Etanercept;Adalimumab;Certolizumab;Infliximab
27 Comparison of Adalimumab and Infliximab Treatment of Rheumatoid Arthritis Unknown status NCT00216177 Phase 4 Infliximab;Adalimumab
28 Ultrasonographic Monitoring of Response to Infliximab in Patients With Rheumatoid Arthritis Unknown status NCT01282528 Phase 4
29 Effect of Tocilizumab to the Cellular Immune Response to Influenza Vaccine Unknown status NCT01980836 Phase 4
30 Bucillamine Study of Holding Remission After Infliximab Dose-off Unknown status NCT00716248 Phase 4 bucillamine;methotrexate
31 RHYTHM (Formerly Escape II Myocardium) Unknown status NCT01548768 Phase 4 TNF inhibitors;DMARDs
32 Very Early Versus Delayed Etanercept in Patients With RA Unknown status NCT02433184 Phase 4 Etanercept;Methotrexate;Sulfasalazine;Hydroxychloroquine;Etanercept;Methotrexate
33 Efficacy and Safety of Adalimumab 80 mg Every Other Week With Methotrexate Unknown status NCT01270035 Phase 4 Adalimumab
34 Birmingham Hip Resurfacing (BHR) Study: Implantation of a Hip Resurfacing Endoprosthesis Unknown status NCT00180206 Phase 4
35 Gait Analysis of Ankle Arthroplasty and Arthrodesis Unknown status NCT00921076 Phase 4
36 Sensitivity and Specificity of QuantiFeron -TB Gold Test (QFT-G)in Patients With Psoriasis Unknown status NCT01223976 Phase 4
37 Bone Forming at Prosthetic Surfaces. Fingerprint2 Unknown status NCT01623687 Phase 4
38 Corticosteroids as Additive in Temporomandibular Joint (TMJ) Arthrocentesis Unknown status NCT01275014 Phase 4 Dexamethasone;Isotonic saline
39 The Long-term Evaluation of Glucosamine Sulphate Study Unknown status NCT00513422 Phase 4
40 The Effect of Spironolactone on Pain in Older People With Osteoarthritis Unknown status NCT02046668 Phase 4 spironolactone
41 The Post-marketing Surveillance to Evaluate the Efficacy of CHONDRON (Autologous Cultured Chondrocyte) by Arthroscopy Unknown status NCT02539069 Phase 4
42 The Post-marketing Surveillance to Evaluate the Efficacy and Safety of a CHONDRON (Autologous Cultured Chondrocyte) Unknown status NCT02539056 Phase 4
43 Safety and Efficacy of Anti-Pandemic H1N1 Vaccination in Rheumatic Diseases Unknown status NCT01151644 Phase 4
44 Acthar for the Treatment of Systemic Lupus Erythematosus in Patients With a History of Persistently Active Disease Unknown status NCT01753401 Phase 4 Acthar;Placebo for Acthar
45 A Phase 4 Study of Imrecoxib in Treatment of Knee Osteoarthritis Unknown status NCT01985165 Phase 4 Imrecoxib
46 Multi-center Clinical Study of Guli Capsules in the Treatment of Knee Osteoarthritis Unknown status NCT02484508 Phase 4 Guli capsule;Kangguzengsheng capsule
47 Gastro-protective Effect and Pain Relief Effect of Naxozol Compared to Celecoxib in Patients With Osteoarthritis Unknown status NCT02355236 Phase 4 Naproxen/Esomeprazol 500/20mg;Celecoxib 200mg;Naxozol-Placebo;Comparator-Placebo
48 Efficacy of Intra-articular Collagen Injection in Patients With Knee Joint Pain Compared to Normal Saline Injection Unknown status NCT02539095 Phase 4
49 Comparison of Efficacy and Safety of Microfracture and Modified Microfracture Unknown status NCT02539030 Phase 4
50 Validation of a Stress Device for the Knee Unknown status NCT02444663 Phase 4

Search NIH Clinical Center for Arthritis

Inferred drug relations via UMLS 74 / NDF-RT 52 :


Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Arthritis cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: arthritis

Genetic Tests for Arthritis

Genetic tests related to Arthritis:

# Genetic test Affiliating Genes
1 Arthritis 30

Anatomical Context for Arthritis

MalaCards organs/tissues related to Arthritis:

42
Bone, T Cells, Testes, Lung, Skin, B Cells, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Arthritis:

20
Joint, Skin Over The Joint

Publications for Arthritis

Articles related to Arthritis:

(show top 50) (show all 31005)
# Title Authors Year
1
Comparative study of Interleukin-18 (IL-18) serum levels in adult onset Still's disease (AOSD) and systemic onset juvenile idiopathic arthritis (sJIA) and its use as a biomarker for diagnosis and evaluation of disease activity. ( 30886992 )
2019
2
Evaluation of alexithymia in patients affected by rheumatoid arthritis and psoriatic arthritis: A cross-sectional study. ( 30681555 )
2019
3
Sonographic findings from inflammatory arthritis due to antisynthetase syndrome. ( 30810913 )
2019
4
Correction: Community-deliverable exercise and anxiety in adults with arthritis and other rheumatic diseases: a systematic review with meta-analysis of randomised controlled trials. ( 30798296 )
2019
5
Juvenile Arthritis Patients Suffering from Chronic Inflammation Have Increased Activity of Both IDO and GTP-CH1 Pathways But Decreased BH4 Efficacy: Implications for Well-Being, Including Fatigue, Cognitive Impairment, Anxiety, and Depression. ( 30625990 )
2019
6
[Ru(bpy)2(NO)SO3](PF6), a Nitric Oxide Donating Ruthenium Complex, Reduces Gout Arthritis in Mice. ( 30914954 )
2019
7
Effector Functions of CD4+ T Cells at the Site of Local Autoimmune Inflammation-Lessons From Rheumatoid Arthritis. ( 30915067 )
2019
8
Caught in a Trap? Proteomic Analysis of Neutrophil Extracellular Traps in Rheumatoid Arthritis and Systemic Lupus Erythematosus. ( 30915077 )
2019
9
Prescribing Trend of Antirheumatic Drugs in Taiwan and Risk of Cardiovascular Disease in Patients with Rheumatoid Arthritis: A Nationwide Cohort Study. ( 30915358 )
2019
10
Efficient Therapeutic Function and Mechanisms of Human Polyclonal CD8+CD103+Foxp3+ Regulatory T Cells on Collagen-Induced Arthritis in Mice. ( 30915372 )
2019
11
Is self-assessment by patients of disease activity acceptable over the long term in rheumatoid arthritis? A 3-year follow-up of 771 patients. ( 30915463 )
2019
12
A new geometric model to quantify the area of glenoid bone defect and medialisation of the native joint line in glenohumeral arthritis. ( 30915555 )
2019
13
Decreased Injection Site Pain Associated with Phosphate-Free Etanercept Formulation in Rheumatoid Arthritis or Psoriatic Arthritis Patients: A Randomized Controlled Trial. ( 30915626 )
2019
14
Efficacy and safety profile of intravenous tocilizumab versus intravenous abatacept in treating female Saudi Arabian patients with active moderate-to-severe rheumatoid arthritis. ( 30915650 )
2019
15
Diagnostic values of serum IL-10 and IL-17 in rheumatoid arthritis and their correlation with serum 14-3-3η protein. ( 30915732 )
2019
16
Influences of miR-320a on proliferation and apoptosis of fibroblast-like synoviocytes in rheumatoid arthritis through targeting MAPK-ERK1/2. ( 30915733 )
2019
17
Bioinformatics Analysis and Identification of Genes and Molecular Pathways Involved in Synovial Inflammation in Rheumatoid Arthritis. ( 30916045 )
2019
18
Association between tumor necrosis factor polymorphisms and rheumatoid arthritis as well as systemic lupus erythematosus: a meta-analysis. ( 30916218 )
2019
19
Association of Ustekinumab vs TNF Inhibitor Therapy With Risk of Atrial Fibrillation and Cardiovascular Events in Patients With Psoriasis or Psoriatic Arthritis. ( 30916734 )
2019
20
Mental Health and Rheumatoid Arthritis: Toward Understanding the Emotional Status of People with Chronic Disease. ( 30886858 )
2019
21
Malignancy risk in Australian rheumatoid arthritis patients treated with anti-tumour necrosis factor therapy: an update from the Australian Rheumatology Association Database (ARAD) prospective cohort study. ( 30886989 )
2019
22
Tissue metabolite of type I collagen, C1M, and CRP predicts structural progression of rheumatoid arthritis. ( 30886991 )
2019
23
Living life precariously with rheumatoid arthritis - a mega-ethnography of nine qualitative evidence syntheses. ( 30886993 )
2019
24
Real world long-term impact of intensive treatment on disease activity, disability and health-related quality of life in rheumatoid arthritis. ( 30886994 )
2019
25
Relapse rates after elective discontinuation of anti-TNF therapy in rheumatoid arthritis: a meta-analysis and review of literature. ( 30886998 )
2019
26
Vascular Arginase Is a Relevant Target to Improve Cerebrovascular Endothelial Dysfunction in Rheumatoid Arthritis: Evidence from the Model of Adjuvant-Induced Arthritis. ( 30887278 )
2019
27
Early arthritis clinic is cost-effective, improves outcomes and reduces biologic use. ( 30888567 )
2019
28
Septic Arthritis of the Native Ankle. ( 30889008 )
2019
29
Flexible two-layer dissolving and safing Microneedle transdermal of Neurotoxin: A biocomfortable attempt to treat Rheumatoid Arthritis. ( 30890451 )
2019
30
Epidemiology of rheumatoid arthritis, clinical aspects and socio-economic determinants in Pakistani patients: A systematic review and meta-analysis. ( 30890833 )
2019
31
Are There Any Common Genetic Risk Markers for Rheumatoid Arthritis and Periodontal Diseases? A Case-Control Study. ( 30890897 )
2019
32
Discovery of a JAK1/3 Inhibitor and Use of a Prodrug To Demonstrate Efficacy in a Model of Rheumatoid Arthritis. ( 30891131 )
2019
33
Studying the effects of haplotype partitioning methods on the RA-associated genomic results from the North American Rheumatoid Arthritis Consortium (NARAC) dataset. ( 30891314 )
2019
34
Diagnostic Dilemma of Disseminated Histoplasmosis Mimicking Hemophagocytosis Lymphohistiocytosis in Patient with Rheumatoid Arthritis on Anti-TNF Therapy: Case Report and Review of the Literature. ( 30891325 )
2019
35
Optimal Biologic Selection for Treatment of Psoriatic Arthritis: the Approach to Precision Medicine. ( 30891646 )
2019
36
Disease burden in osteoarthritis (OA) is similar to rheumatoid arthritis (RA) at initial rheumatology visit and significantly greater 6-months later. ( 30891933 )
2019
37
Changes in Alcohol Use and Associations with Disease Activity, Health Status, and Mortality in Rheumatoid Arthritis. ( 30891938 )
2019
38
Circulating Insulin-like Growth Factor-1 Levels in Patients with Rheumatoid Arthritis : A Meta-analysis. ( 30892152 )
2019
39
Primus inter pares: the choice of biologic drugs in rheumatoid arthritis. ( 30892618 )
2019
40
Association between socioeconomic status and comorbidities among patients with rheumatoid arthritis: results of a nationwide cross-sectional survey. ( 30892622 )
2019
41
The autoantibody response to cyclic citrullinated collagen type II peptides in rheumatoid arthritis. ( 30892636 )
2019
42
Elevated matrix metalloproteinase-3 level may affect hearing function in patients with rheumatoid arthritis. ( 30893257 )
2019
43
Efficacy and cost savings with the use of a minimal sedation / anxiolysis protocol for intra-articular corticosteroid injections in children with juvenile idiopathic arthritis: a retrospective review of prospectively collected data. ( 30894194 )
2019
44
Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan. ( 30894208 )
2019
45
Hypoxia-induced miR-191-C/EBPβ signaling regulates cell proliferation and apoptosis of fibroblast-like synoviocytes from patients with rheumatoid arthritis. ( 30894209 )
2019
46
Tofacitinib: A Review in Psoriatic Arthritis. ( 30895473 )
2019
47
Anti-cyclic citrullinated peptide antibody is highly associated with rheumatoid factor and radiological defects in rheumatoid arthritis patients. ( 30896663 )
2019
48
Exenatide Ameliorates Inflammatory Response in Human Rheumatoid Arthritis Fibroblast-Like Synoviocytes. ( 30897288 )
2019
49
Diallyl Trisulfide can induce fibroblast-like synovial apoptosis and has a therapeutic effect on collagen-induced arthritis in mice via blocking NF-κB and Wnt pathways. ( 30897500 )
2019
50
Golimumab for Rheumatoid Arthritis. ( 30897745 )
2019